These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10186468)

  • 1. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
    Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
    Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
    Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
    Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of illness and its predictors for Parkinson's disease in Germany.
    Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
    Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy].
    Dodel RC; Pepperl S; Köhne-Volland R; Szucs T; Werhahn KJ; Noachtar S; Oertel WH
    Med Klin (Munich); 1996 Jul; 91(7):479-85. PubMed ID: 8756119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
    Dodel RC; Berger K; Oertel WH
    Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in resource utilization for Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
    J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
    Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
    Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom.
    Findley L; Aujla M; Bain PG; Baker M; Beech C; Bowman C; Holmes J; Kingdom WK; MacMahon DG; Peto V; Playfer JR
    Mov Disord; 2003 Oct; 18(10):1139-45. PubMed ID: 14534917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug and treatment costs in Parkinson's disease patients in Sweden.
    Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
    Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
    Prado M; Jamora RD
    J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
    Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
    J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.